Partial adherence to antipsychotic medication impacts the course of illness in patients with schizophrenia: A review

Primary Care Companion to the Journal of Clinical Psychiatry

Volumn 11, Issue 4, 2009, Pages 147-154

  Masand, Prakash S ^a   Roca, Miquel ^b   Turner, Martin S ^c   Kane, John M ^d  

^a DUKE UNIVERSITY MEDICAL CENTER   (United States)

^b UNIVERSITAT DE LES ILLES BALEARS   (Spain)

^c Larkfield Centre   (United Kingdom)

^d ZUCKER HILLSIDE HOSPITAL   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ATYPICAL ANTIPSYCHOTIC AGENT; LONG ACTING DRUG; NEUROLEPTIC AGENT;

CLINICAL PRACTICE; DISEASE COURSE; DOCTOR PATIENT RELATION; DRUG BLOOD LEVEL; DRUG COST; DRUG WITHDRAWAL; HEALTH CARE COST; HUMAN; OUTCOME ASSESSMENT; PATIENT COMPLIANCE; PRIMARY MEDICAL CARE; PSYCHOSIS; RELAPSE; REVIEW; RISK FACTOR; SCHIZOPHRENIA; SYSTEMATIC REVIEW; TREATMENT REFUSAL;

EID: 74549129561     PISSN: 15235998     EISSN: 1555211X     Source Type: Journal    
DOI: 10.4088/PCC.08r00612     Document Type: Review

References (77)

1. Weiden PJ, Kozma C, Grogg A, et al. Partial compliance and risk of rehospitalization among California Medicaid patients with schizophrenia. Psychiatr Serv 2004;55:886-891
2. San L, Ciudad A, Alvarez E, et al. Symptomatic remission and social/ vocational functioning in outpatients with schizophrenia: prevalence and associations in a cross-sectional study. Eur Psychiatry 2007;22:490-498
3. Kane JM. Utilization of long-acting antipsychotic medication in patient care. CNS Spectr 2006;11:1-7
4. Robinson D, Woerner MG, Alvir JM, et al. Predictors of relapse following response from a first episode of schizophrenia or schizoaffective disorder. Arch Gen Psychiatry 1999;56:241-247
5. Masand PS, Narasimhan M. Improving adherence to antipsychotic pharmacotherapy. Curr Clin Pharmacol 2006;1:47-56
6. Perkins DO. Adherence to antipsychotic medications. J Clin Psychiatry 1999;60(suppl 21):25-30
7. Kane JM. Problems of compliance in the outpatient treatment of schizophrenia. J Clin Psychiatry 1983;44(6 Pt 2):3-6
8. Buchanan A. A two-year prospective study of treatment compliance in patients with schizophrenia. Psychol Med 1992;22:787-797
9. Oehl M, Hummer M, Fleischhacker WW. Compliance with antipsy-chotic treatment. Acta Psychiatr Scand Suppl 2000;407:83-86
10. Aronson JK. Editors' view. Compliance, concordance, adherence. Br J Clin Pharmacol 2007;63:383-384
11. Young JL, Zonana H V, Shepler L. Medication noncompliance in schizophrenia: codification and update. Bull Am Acad Psychiatry Law 1986;14: 105-122
12. Valenstein M, Copeland LA, Blow FC, et al. Pharmacy data identify poorly adherent patients with schizophrenia at increased risk for admission. Med Care 2002;40:630-639
13. Bebbington PE. The content and context of compliance. Int Clin Psychopharmacol 1995;9(suppl 5):41-50
14. Marder SR. Overview of partial compliance. J Clin Psychiatry 2003;64(suppl 16):3-9
15. Weiden P, Rapkin B, Mott T, et al. Rating of medication influences (ROMI) scale in schizophrenia. Schizophr Bull 1994;20:297-310
16. Fenton WS, Blyler CR, Heinssen RK. Determinants of medication compliance in schizophrenia: empirical and clinical findings. Schizophr Bull 1997;23:637-651
17. McCombs JS, Nichol MB, Stimmel GL, et al. Use patterns for antipsy-chotic medications in Medicaid patients with schizophrenia. J Clin Psychiatry 1999;60(suppl 19): 5-11
18. Docherty JP, Grogg AL, Kozma C, et al. Antipsychotic partial compliance: impact on clinical outcomes in schizophrenia: In: Program and Abstracts of the 156th annual meeting of the American Psychiatric Association; May 17-22, 2003; San Francisco, Calif. Abstract NR172
19. Velligan DI, Lam F, Ereshefsky L, et al. Perspectives on medication adherence and atypical antipsychotic medications. Psychiatr Serv 2003;54:665-667
20. Valenstein M, Barry KL, Blow FC, et al. Agreement between seriously mentally ill veterans and their clinicians about medication compliance. Psychiatr Serv 1998;49:1043-1048
21. Byerly M, Fisher R, Whatley K, et al. A comparison of electronic monitoring vs clinician rating of antipsychotic adherence in outpatients with schizophrenia. Psychiatry Res 2005;133:129-133
22. Woltmann EM, Valenstein M, Welsh DE, et al. Using pharmacy data on partial adherence to inform clinical care of patients with serious mental illness. Psychiatr Serv 2007;58:864-867
23. Velligan DI, Wang M, Diamond P, et al. Relationships among subjective and objective measures of adherence to oral antipsychotic medications. Psychiatr Serv 2007;58:1187-1192
24. Lacro JP, Dunn LB, Dolder CR, et al. Prevalence of and risk factors for medication nonadherence in patients with schizophrenia: a comprehensive review of recent literature. J Clin Psychiatry 2002;63(10):892-909
25. Giner J, Roca M, Cañas F, et al. New insights in the therapeutic adherence in schizophrenia. Eur Neuropsychopharmacol 2004;14(suppl 3): S266
26. Turner M, Masand P, Roca M, et al. Results of a study on psychiatrists' perceptions of adherence to medication among patients with schizophrenia: the ADHES survey. Eur Neuropsychopharmacol 2007;17(suppl 4): S455-S456
27. Kim SW, Yoon JS, Choi SK. Survey of medication adherence in patients with schizophrenia-Korean ADHES data. Hum Psychopharmacol 2006;21:533-537
28. Roca M, Cañas F, Olivares J, et al. Treatment adherence in schizophrenia: Spanish Clinical Consensus. Actas Esp Psiquiatr 2007;35:1-6
29. Ayuso-Gutierrez JL, del Rio Vega JM. Factors influencing relapse in the long-term course of schizophrenia. Schizophr Res 1997;28:199-206
30. Steadman HJ, Mulvey E P, Monahan J, et al. Violence by people dis- charged from acute psychiatric inpatient facilities and by others in the same neighborhoods. Arch Gen Psychiatry 1998;55:393-401
31. Lieberman JA, Sheitman B, Chakos M, et al. The development of treat ment resistance in patients with schizophrenia: a clinical and pathophysiologic perspective. J Clin Psychopharmacol 1998; 18(2 suppl 1):20S-24S
32. Wyatt RJ. Neuroleptics and the natural course of schizophrenia. Schizophr Bull 1991;17:325-351
33. Olfson M, Mechanic D, Hansell S, et al. Predicting medication noncom-pliance after hospital discharge among patients with schizophrenia. Psychiatr Serv 2000;51:216-222
34. Weiden PJ, Olfson M. Cost of relapse in schizophrenia. Schizophr Bull 1995;21:419-429
35. Keith SJ, Kane JM. Partial compliance and patient consequences in schizophrenia: our patients can do better. J Clin Psychiatry 2003;64(11): 1308-1315
36. McGlashan TH. Duration of untreated psychosis in first-episode schizophrenia: marker or determinant of course? Biol Psychiatry 1999;46: 899-907
37. Gilmer T P, Dolder CR, Lacro J P, et al. Adherence to treatment with anti-psychotic medication and health care costs among Medicaid beneficiaries with schizophrenia. Am J Psychiatry 2004;161:692-699
38. Knapp M, King D, Pugner K, et al. Non-adherence to antipsychotic medication regimens: associations with resource use and costs. Br J Psychiatry 2004;184:509-516
39. Marcus SC, Olfson M. Outpatient antipsychotic treatment and inpatient costs of schizophrenia. Schizophr Bull 2008;34:173-180
40. Hui CL, Chen E Y, Kan CS, et al. Detection of non-adherent behaviour in early psychosis. Aust N Z J Psychiatry 2006;40:446-451
41. Perkins DO, Johnson JL, Hamer RM, et al. HGDH Research Group. Predictors of antipsychotic medication adherence in patients recovering from a first psychotic episode. Schizophr Res 2006;83:53-63
42. Kamali M, Kelly BD, Clarke M, et al. A prospective evaluation of adherence to medication in first episode schizophrenia. Eur Psychiatry 2006; 21:29-33
43. Tandon R. In conclusion: does antipsychotic treatment modify the long-term course of schizophrenic illness? J Psychiatr Res 1998;32:251-253
44. Robinson DG, Woerner MG, Alvir JM, et al. Predictors of treatment response from a first episode of schizophrenia or schizoaffective disorder. Am J Psychiatry 1999;156:544-549
45. Malla A, Norman R, Schmitz N, et al. Predictors of rate and time to remission in first-episode psychosis: a two-year outcome study. Psychol Med 2006;36:649-658
46. Robinson DG, Woerner MG, Alvir JM, et al. Predictors of medication discontinuation by patients with first-episode schizophrenia and schizoaf-fective disorder. Schizophr Res 2002;57:209-219
47. Coldham EL, Addington J, Addington D. Medication adherence of individuals with a first episode of psychosis. Acta Psychiatr Scand 2002;106: 286-290
48. Mojtabai R, Lavelle J, Gibson PJ, et al. Gaps in use of antipsychotics after discharge by first-admission patients with schizophrenia, 1989 to 1996. Psychiatr Serv 2002;53:337-339
49. Verdoux H, Lengronne J, Liraud F, et al. Medication adherence in psychosis: predictors and impact on outcome: a 2-year follow-up of first-admitted subjects. Acta Psychiatr Scand 2000;102:203-210
50. Tacchi MJ, Scott J. Improving Adherence in Schizophrenia and Bipolar Disorders. Chichester, UK: John Wiley & Sons; 2005
51. Narasimhan M, Pae CU, Masand N, et al. Partial compliance with anti-psychotics and its impact on patient outcomes. Int J Psych Clin Pract 2007;11:102-111
52. McEvoy J P, Johnson J, Perkins D, et al. Insight in first-episode psychosis. Psychol Med 2006;36:1385-1393
53. Kampman O, Laippala P, Vaananen J, et al. Indicators of medication compliance in first-episode psychosis. Psychiatry Res 2002;110:39-48
54. Lecomte T, Spidel A, Leclerc C, et al. Predictors and profiles of treatment non-adherence and engagement in services problems in early psychosis. Schizophr Res 2008;102:295-302
55. Karow A, Czekalla J, Dittmann RW, et al. Association of subjective well-being, symptoms, and side effects with compliance after 12 months of treatment in schizophrenia. J Clin Psychiatry 2007;68(1):75-80
56. Aquila R, Weiden PJ, Emanuel M. Compliance and the rehabilitation alliance. J Clin Psychiatry 1999;60(suppl 19):23-27
57. Dolder CR, Lacro J P, Dunn LB, et al. Antipsychotic medication adherence: is there a difference between typical and atypical agents? Am J Psychiatry 2002;159:103-108
58. Jones PB, Barnes TR, Davies L, et al. Randomized controlled trial of the effect on quality of life of second- vs first-generation antipsychotic drugs in schizophrenia: Cost Utility of the Latest Antipsychotic Drugs in Schizophrenia Study (CUtLASS 1). Arch Gen Psychiatry 2006;63: 1079-1087
59. Nasrallah HA. The case for long-acting antipsychotic agents in the post-CATIE era. Acta Psychiatr Scand 2007;115:260-267
60. Valenstein M, Copeland LA, Owen R, et al. Adherence assessments and the use of depot antipsychotics in patients with schizophrenia. J Clin Psychiatry 2001;62(7):545-551
61. Kane JM. Review of treatments that can ameliorate nonadherence in patients with schizophrenia. J Clin Psychiatry 2006;67(suppl 5):9-14
62. Fleischhacker WW, Eerdekens M, Karcher K, et al. Treatment of schizophrenia with long-acting injectable risperidone: a 12-month open-label trial of the first long-acting second-generation antipsychotic. J Clin Psychiatry 2003;64(10):1250-1257
63. Turner M, Eerdekens E, Jacko M, et al. Long-acting injectable risperi-done: safety and efficacy in stable patients switched from conventional depot antipsychotics. Int Clin Psychopharmacol 2004;19:241-249
64. Schmauss M, Sacchetti E, Kahn J P, et al. Efficacy and safety of risper-idone long-acting injectable in stable psychotic patients previously treated with oral risperidone. Int Clin Psychopharmacol 2007;22:85-92
65. Chue P, Emsley R. Long-acting formulations of atypical antipsychotics: time to reconsider when to introduce depot antipsychotics. CNS Drugs 2007;21:441-448
66. Weiden PJ, Schooler NR, Weedon JC, et al. An RCT of long-acting vs oral antipsychotic route in "first-episode" schizophrenia: effects on acceptance and attitudes. Presented at the 161st annual meeting of the American Psychiatric Association; May 3-8, 2008; Washington DC. Abstract NR1-087
67. Mutsatsa SH, Joyce EM, Hutton SB, et al. Clinical correlates of early medication adherence: West London first episode schizophrenia study. Acta Psychiatr Scand 2003;108:439-446
68. Weiss KA, Smith TE, Hull JW, et al. Predictors of risk of nonadherence in outpatients with schizophrenia and other psychotic disorders. Schizophr Bull 2002;28:341-349
69. Kampman O, Lehtinen K. Compliance in psychoses. Acta Psychiatr Scand 1999;100:167-175
70. Garety PA, Craig TKJ, Dunn G, et al. Specialised care for early psychosis: symptoms, social functioning and patient satisfaction-randomised controlled trial. Br J Psychiatry 2006;188:37-45
71. Haynes RB, McKibbon KA, Kanani R. Systematic review of randomised trials of interventions to assist patients to follow prescriptions for medications. Lancet 1996;348:383-386
72. Kemp R, Hayward P, Applewhaite G, et al. Compliance therapy in psychotic patients: randomised controlled trial. Br Med J 1996;312:345-349
73. Tay SE. Compliance therapy: an intervention to improve inpatients' attitudes toward treatment. J Psychosoc Nurs Ment Health Serv 2007;45(6): 29-37
74. Wyatt RJ, Henter ID. The effects of early and sustained intervention on the long-term morbidity of schizophrenia. J Psychiatr Res 1998;32: 169-177
75. Wyatt RJ, Green MF, Tuma AH. Long-term morbidity associated with delayed treatment of first admission schizophrenic patients: a re-analysis of the Camarillo State Hospital data. Psychol Med 1997;27:261-268
76. Wyatt RJ, Damiani LM, Henter ID. First-episode schizophrenia: early intervention and medication discontinuation in the context of course and treatment. Br J Psychiatry Suppl 1998;172:77-83
77. Lieberman JA, Koreen AR, Chakos M, et al. Factors influencing treatment response and outcome of first-episode schizophrenia: implications for understanding the pathophysiology of schizophrenia. J Clin Psychiatry 1996;57(suppl 9):5-9